Jyong Biotech Ltd. (NASDAQ:MENS – Get Free Report)’s stock price was down 8% during trading on Wednesday . The company traded as low as $36.61 and last traded at $37.39. Approximately 427,985 shares traded hands during trading, an increase of 49% from the average daily volume of 287,165 shares. The stock had previously closed at $40.66.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jyong Biotech in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.
View Our Latest Analysis on Jyong Biotech
Jyong Biotech Trading Down 9.7%
About Jyong Biotech
OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.
Recommended Stories
- Five stocks we like better than Jyong Biotech
- Are Penny Stocks a Good Fit for Your Portfolio?
- Carving Up Profits: 3 Food Stocks on the Thanksgiving Table
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- C3.ai’s Reset: Why New Leadership Could Spark a Turnaround
- Stock Analyst Ratings and Canadian Analyst Ratings
- CleanSpark Secures $1.15B, Stock Drops—Here’s Why It’s an Opportunity
Receive News & Ratings for Jyong Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jyong Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
